Cabaletta Bio Reports One-Year Rese-cel Responses in All Six Dermatomyositis Patients in Phase 1/2 Study

Bitget2026/11/08 15:00

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold. Trade now!

A welcome pack worth 6200 USDT for new users! Sign up now!

Cabaletta Bio announced Phase 1/2 rese-cel results for presentation at ACR Convergence 2026 on November 8-9.
Dermatomyositis patients maintained improvement without immunomodulators through one year; biopsied lupus nephritis patients achieved remission without those drugs.
Most systemic sclerosis patients improved without immunomodulators through one year; patients with associated lung disease showed better lung function.
Safety findings across 71 patients showed mostly absent or mild cytokine release syndrome; most patients experienced no treatment-associated neurotoxicity.
Registrational adult myositis results are expected in the second half of 2027, with a myositis biologics application planned for early 2028.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Cabaletta Bio Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202611081000PRIMZONEFULLFEED9872789) on November 08, 2026, and is solely responsible for the information contained therein.

Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.

Understand the market, then trade.

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold.

Trade now！

Cabaletta Bio Reports One-Year Rese-cel Responses in All Six Dermatomyositis Patients in Phase 1/2 Study

You may also like

Crypto prices